SynthesisMayo Clinic proceedings2021
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.
Open access · bronzeAbstract readMeta-AnalysisSystematic Review
In one paragraph
Synthesis in Mayo Clinic proceedings, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 6 pooled it
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 6 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- Effect of convalescent plasma transfusion on outcomes of coronavirus disease 2019: a meta-analysis with trial sequential analysis.Journal of anesthesia · 2023Pooled it
- Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Pooled it
- Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.JAMA network open · 2022Pooled it
- Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.Transfusion medicine reviews · 2022Pooled it
- Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.BMC infectious diseases · 2021Pooled it
- CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence.European journal of clinical investigation · 2021Pooled it
- Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study.Antimicrobial agents and chemotherapy · 2023Trial
- Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.European journal of internal medicine · 2022Trial
- A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.Nature communications · 2022Trial
- A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.The Journal of clinical investigation · 2021Trial
- Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.PLoS medicine · 2021Trial
- Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.The Journal of clinical investigation · 2021Trial
- Trial
- High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients.Frontiers in immunology · 2021Trial
- Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia.Allergy & rhinology (Providence, R.I.)Trial
- Clinical Outcomes of COVID-19 Convalescent Plasma According to Treatment Timing and ELISA Antibody Levels: A Real-World Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- The Value of Convalescent Plasma Therapy as a Strategy to Decrease Hospitalization in COVID-19 Patients: A Randomized Clinical Trial.Acta medica Philippina · 2026Article
- Rapid Discovery of Potent Neutralizing Antibodies against SARS-CoV-2 through Directed Evolution of SARS-CoV-1 Antibodies.Molecular pharmaceutics · 2025Article
- Immunological orchestration and dysregulation in COVID-19 pneumonia: from viral pathogenesis to precision therapeutics in the post-pandemic era.Folia microbiologica · 2025Review
- Rapid clinical effects of convalescent plasma therapy in severe COVID-19 acute respiratory distress syndrome (ARDS).Intensive care medicine · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Update of
Authors and funding
23 authors at 13 institutions in 1 country.
Stephen A KlassenDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.
Jonathon W SenefeldDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.
Patrick W JohnsonDepartment of Health Sciences Research, Mayo Clinic, Jacksonville, FL.
Rickey E CarterDepartment of Health Sciences Research, Mayo Clinic, Jacksonville, FL.
Chad C WigginsDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.
Shmuel ShohamDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.
Brenda J GrossmanDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO.
Jeffrey P HendersonDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO; Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO.
James MusserDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX; Center for Molecular and Translational Human Infectious Diseases, Houston Methodist Research Institute, Houston, TX; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY.
Eric SalazarDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY.
William R HartmanDepartment of Anesthesiology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Icahn School of Medicine at Mount Sinai, New York, NY.
Nicole M BouvierDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.
Sean T H LiuDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.
Liise-Anne PirofskiDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.
Sarah E BakerDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.
Noud van HelmondDepartment of Anesthesiology, Cooper Medical School of Rowan University, Cooper University Health Care, Camden, NJ.
R Scott WrightDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN; Director, Human Research Protection Program, Mayo Clinic, Rochester, MN.
DeLisa FairweatherDepartment of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL.
Katelyn A BrunoDepartment of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL.
Zhen WangEvidence-Based Practice Center, Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Mayo Clinic, Rochester, MN.
Nigel S PanethDepartment of Epidemiology and Biostatistics, Michigan State University, East Lansing; Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing.
Arturo CasadevallDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Michael J JoynerDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN. Electronic address: joyner.michael@mayo.edu.
Mayo Clinic in Arizona · USIcahn School of Medicine at Mount Sinai · USJacksonville College · USJohns Hopkins University · USMayo Clinic in Florida · USWashington University in St. Louis · USAlbert Einstein College of Medicine · USCooper Medical School of Rowan University · USCornell University · USHouston Methodist · USMayo Clinic · USMichigan State University · USUniversity of Wisconsin–Madison · US
Funding
DIABETES AND METABOLISMT32DK007352 · NIDDK · MAYO CLINIC ROCHESTER · PI MICHAEL D. JENSEN · 1986 to 2026
$9.4MSynergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4MVariant Hemoglobin and Cardiorespiratory Regulation in HumansR35HL139854 · NHLBI · MAYO CLINIC ROCHESTER · PI JOYNER, MICHAEL J · 2018 to 2024
$5.8MConjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision SupplementR01AI152078 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2020 to 2024
$5.1MRole of viral mitophagosomes in driving sex differences in myocarditisR21AI145356 · NIAID · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA, SIN, JON · 2019 to 2020
$463kAdipose-derived biogenic nanoparticles for treatment of myocarditis/DCM(MPDPI)R21AI152318 · NIAID · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA, WOLFRAM, JOY · 2020 to 2021
$430kSex differences in exercise-induced mitochondrial function during viral myocarditisR21AI154927 · NIAID · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA · 2020 to 2021
$403kSkeletal muscle performance and cellular adaptations to high hemoglobin-oxygen affinityF32HL154320 · NHLBI · MAYO CLINIC ROCHESTER · PI SENEFELD, JONATHON · 2020 to 2021
$117kNHLBI NIH HHS F32 HL154320NHLBI NIH HHS R01 HL059842NHLBI NIH HHS R35 HL139854NIAID NIH HHS R01 AI152078NIAID NIH HHS R21 AI145356NIAID NIH HHS R21 AI152318NIAID NIH HHS R21 AI154927NIDDK NIH HHS T32 DK007352
Abstract
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized patients with COVID-19.
Indexed as
COVID-19COVID-19 SerotherapyHumansImmunization, PassiveMortalitySARS-CoV-2Time-to-Treatment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.